PURPOSE: Blockage of PD-1 with drugs such as nivolumab (Nivo) and pembrolizumab (Pembro) has been successfully implemented in the treatment of Hodgkin lymphoma among other types of tumors. Exorbitant costs hinder access for many patients living in low- and middle-income countries (LMICs). Dose reductions on the basis of pharmacodynamic studies have been used to allow access to these drugs to patients with no further options because of economic constraints. In this study, we aimed to systematically review and assess evidence regarding the efficacy and safety of this adapted intervention. METHODS: An expert librarian designed and conducted a literature search in MEDLINE, Scopus, Web of Science, EMBASE, Cochrane Central, and clinicaltrials.gov. Screening was conducted in a title/abstract and full-text phase independently and in duplicate. Primary outcomes were overall survival, overall response rates (ORRs), and incidence of adverse events (AEs). Data extraction was performed independently and in duplicate as well. A qualitative synthesis was performed and reported in the results. RESULTS: Six studies investigated Nivo as an intervention, two Pembro, and 1 both therapies, with a total of 161 patients overall. One study had a single-arm prospective trial design and the rest a retrospective cohort design. ORR ranged from 66% to 100%, with complete response rates between 38% and 75%. The incidence of AEs was mostly high across all studies ranging from 27% to 93%, most of it composed of grade 1-2 AEs (27%-80%). No study reported health-related quality-of-life outcomes. CONCLUSION: Low-dose anti-PD1 immune checkpoint inhibitors have shown to be adequate candidates for testing of their efficacy in randomized trials and could improve access to these high-cost medications for patients with Hodgkin lymphoma both in LMICs and high-income countries.
13 September 2025 in Transplantation and Cellular Therapy
Hematopoietic stem cell transplantation (SCT) offers curative potential for hematologic diseases but demands rigorous quality management often out of reach in low- and middle-income countries (LMICs). Our institution- the only public academic hospital in Latin America accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) since 2016, with recertifications in 2020 and 2024-has demonstrated that FACT standards can be met through pragmatic, cost-effective adaptations. This review summarizes key strategies for continued maintenance of high-quality transplantation practices, including data management, continuous medical education, as well as cost-effective clinical practices. We also address donor selection approaches, cryopreservation alternatives, and supplementary accreditations. By outlining our FACT accreditation journey and outcomes equivalent to conventional settings, we provide a replicable framework for LMIC centers to achieve international quality benchmarks. Our experience underscores that high-quality SCT and sustained accreditation are attainable in resource-constrained environments, ultimately improving access and survival for patients across the LMICs.
6 November 2025 in Transplantation and Cellular Therapy
Competing risks are common in hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapy research. Competing risks refer to events that cannot co-occur and complicate time-to-event analyses. The typical example of competing risk in the context of HCT and IEC research is treatment-related mortality, which competes with disease relapse. In this primer, we first aim to introduce - in a clinician-friendly fashion - the core concepts underlying the statistical modelling of competing risks. Next, we propose a practical, step-by-step guide to analyze time-to-event outcomes in the context of competing risks using the open access R environment. Relevant R packages are introduced, enabling the generation of publication-ready tables and figures. We hope our manuscript will encourage more robust analyses in the fields of HCT and IEC therapy when competing risks are at play.
24 November 2024 in British Journal of Haematology